Spyre Therapeutics, Inc.
SYRE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $5,799,714 | $908,627 | $972,692 | $1,094,803 |
| - Cash | $64,897 | $81,659 | $48,493 | $89,423 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $5,734,817 | $826,968 | $924,199 | $1,005,380 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$45,247 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$11,183 | -$51,935 | -$53,567 | -$61,253 |
| % Margin | – | – | – | – |
| Net Income | -$11,183 | -$36,717 | -$44,773 | -$56,296 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.15 | -0.6 | -0.13 | -0.15 |
| % Growth | 75% | -361.5% | 13.3% | – |
| Operating Cash Flow | -$37,117 | -$46,563 | -$40,994 | -$37,199 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$37,117 | -$46,563 | -$40,994 | -$37,199 |